Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma

Integrative Cancer Therapies

Volumn 5, Issue 1, 2006, Pages 40-47

  Burzynski, Stanislaw R ^a   Janicki, Tomasz J ^a   Weaver, Robert A ^a   Burzynski, Barbara ^a  

^a Burzynski Clinic   (United States)

Author keywords

ANP; Antineoplastons; Astrocytoma; Brain tumor; Brainstem glioma; GBM; Glioblastoma; Glioma

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; ANTINEOPLASTON AS2-1;

ADOLESCENT; ADULT; ANAPLASTIC CARCINOMA; ANEMIA; ARTICLE; BRAIN STEM TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; BENZENEACETAMIDES; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; GLUTAMINE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHENYLACETATES; PIPERIDONES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 32944478642     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735405285380     Document Type: Article

References (31)

1. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998 ; 40: 265-271.
2. Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocytic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer. 2000 ; 89: 1569-1576.
3. Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999 ; 43: 959-964.
4. Guillamo JS, Doz F, Delattre JY. Brain stem gliomas. Curr Opin Neurol. 2001 ; 14: 711-715.
5. Reddy AT. Advances in biology and treatment of childhood brain tumors. Curr Neurol Neurosci Rep. 2001 ; 1: 137-143.
6. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomidein malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002 ; 20: 4684-4691.
7. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent, diffuse, intrinsic brain stem glioma: a preliminary report. Drugs R D. 2003 ; 4: 91-101.
8. Burzynski SR, Weaver RA, Bestak M, et al. Long-term survival in phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma. Neurooncology. 2004 ; 6: 386.
9. Burzynski SR, Lewy RI, Weaver R, et al. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integr Cancer Ther. 2004 ; 3: 257-261.
10. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 (ANP) of high grade recurrent and progressive brain stem gliomas. Paper presented at: 16th International Congress on Anti-cancer Treatment ; February 1-4, 2005 ; Paris, France.
11. Burzynski SR, Weaver RA, Janicki TJ, Burzynski B, Jurida GF. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Paper presented at: Second Quadrennial Meeting of the World Federation of Neurooncology ; May 5-8, 2005 ; Edinburgh, UK.
12. Burzynski SR. The present state of antineoplaston research (1). Integr Cancer Ther. 2004 ; 3: 47-58.
13. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther. 2005 ; 4: 168-177.
14. Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, ed. Recent Advances in Chemotherapy. Munich, Germany: Futuramed ; 1992.
15. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest. 1999 ; 18: 1-10.
16. Freeman CR, Perilongo G. Chemotherapy for brain stem gliomas. Childs Nerv Syst. 1999 ; 15: 545-553.
17. Freeman CR, Kepner J, Kun LE, et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys. 2000 ; 47: 561-564.
18. Bouffet E, Raquin M, Doz F, et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer. 2000 ; 88: 685-692.
19. Broniscer A, Leite CC, Lanchote VL, Machado TM, Cristofani LM. Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. J Clin Oncol. 2000 ; 18: 1246-1253.
20. Broniscer A, Iacono L, Chintagumpala M, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005 ; 103: 133-139.
21. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000 ; 18: 708-715.
22. Baumann F, Bjeljac M, Kollias SS, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol. 2004 ; 67: 191-200.
23. Glass J, Gruber M, Nirenberg A, et al. Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma. In: Proceedings of the American Society of Clinical Oncology. Alexandria, Va: American Society of Clinical Oncology ; 1999. Abstract 551.
24. Wen PY, Yung WKA, Lamborn K, et al. Phase I/II study of imatinib mesylate (ST1571) for patients with recurrent malignant gliomas (NABTC 99-08). Neurooncology. 2004 ; 6: 385.
25. van den Bent MJ, Brandes AA, van Oosterom M, et al. Multicentre phase II study of imatinib mesylate (Gleevec) in patients with recurrent glioblastoma: an EORTC NDDG/BTG intergroup study. Neurooncology. 2004 ; 6: 383.
26. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004 ; 22: 133-142.
27. Uhm JH. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. In: Proceedings of the American Society of Clinical Oncology. Alexandra, Va: American Society of Clinical Oncology ; 2004. Abstract 1505.
28. Volgelbaum MA, Peereboom D, Stevens GHJ, Barnett GH, Brewer C. Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme: results of a phase II study. Neurooncology. 2004 ; 6: 384.
29. Fisher PG, Buffler PA. Malignant gliomas in 2005: where to GO from here? JAMA. 2005 ; 293: 615-617.
30. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005 ; 5: 275-284.
31. Richardson MA, Russell NC, Sanders T, Barrett R, Salverson C. Assessment of outcomes at alternative cancer clinics: a feasible study. J Altern Complement Med. 2001 ; 7: 19-32.